课题基金 / 基金详情

ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL

ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL
患有 0-II 期 ER 阳性乳腺癌的绝经后女性依西美坦的替代剂量：一项随机术前试验
批准号：
9931092
负责人：
POWEL BROWN
金额：
$3.03万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
项目状态：
已结题
起止时间：
2015-08-01 至 2020-07-31
来源：
https://reporter.nih.gov/project-details/9931092
关键词：
AddressBenignClinical TrialsDoseDouble-Blind MethodEstradiolEstrogen receptor positiveExemestaneHistologicIntraepithelial NeoplasiaOperative Surgical ProceduresPatientsPharmaceutical PreparationsPharmacogeneticsPhasePostmenopauseProteomicsRandomizedRegimenSafetySerumStructureTimeTissue SampleTissuesToxic effectWomancirculating biomarkersmalignant breast neoplasmneoplastic celltissue biomarkers

项目摘要

项目成果

POWEL BROWN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This clinical trial is a pre-surgical Phase IIb, randomized, double-blind, multi-centric study for postmenopausal patients with histologically confirmed ER-positive breast cancer (Stage 0-II) comparing the Exemestane standard dose regimen versus two alternative, less frequent dose regimens. The clinical trial will address alternate dosing of Exemestane results in non-inferior reductions in serum estradiol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
海外基金